England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics
Executive Summary
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.
You may also be interested in...
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
UK SMEs Can Help Restock The AMR Toolbox, But Only If The ‘Broken Market’ Is Fixed
The UK must build greater capacity and offer funding to support small but “highly innovative” biotechs, which are instrumental in developing solutions to combat antimicrobial resistance, the chief executive of Scotland’s NovaBiotics argues.
Shionogi Renews 10-Year Goal After Infectious Disease Success
Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals ahead of schedule, its new strategy focuses on HIV and COVID-19 and new product launches.